Phase 3 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a tissue test
- People whose cancer is located in the chest portion of the oesophagus, has not spread to distant parts of the body, and is considered suitable for complete surgical removal based on specific staging criteria (confirm with trial site)
- People with no signs of cancer spread to the lymph nodes near the collarbone
- People who are fully active or have only minor restrictions on physical activity, as measured by a standard medical scale (ECOG score of 0 or 1)
- People aged 18 to 75 years, of any gender
- People who are willing and able to sign a written consent form for the trial
- People whose liver, kidneys, and other organs are functioning well enough to participate (confirm with trial site)
- Women who could become pregnant must have a negative pregnancy test taken within 72 hours before the first treatment dose
- People who are willing to provide tissue, blood, and urine samples, including a fresh tissue sample taken within 28 days before treatment begins
- People who have not previously received any systemic or local treatment for oesophageal cancer
Who may not be able to join:
- People for whom oesophageal surgery is not medically suitable or is otherwise not recommended
- People who have previously had surgery, radiotherapy, immunotherapy, or chemotherapy for oesophageal cancer
- People who currently have, or have a history of, an autoimmune disease
- People who require ongoing treatment with steroid medications or other drugs that suppress the immune system
- People who have a history of symptomatic interstitial lung disease (a condition causing scarring or inflammation in the lungs)
- People who have a known allergy to any components of the study drug
- People who are currently pregnant or breastfeeding
- People who have previously received chemotherapy, radiotherapy, targeted therapy, or immunotherapy for this cancer or any other past cancer
- People with other underlying health conditions that, in the trial doctor's judgment, could make the study treatment unsafe or make it difficult to monitor side effects
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 18622221069
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event Free Survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.